FALSE 2020 Q1 AMEDISYS INC 0000896262--12-31 0.001 5,000,000————0.001 60,000,000 74 74 60 30 30 58 1.3 2.0 Fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate for an interest period of one month plus 1% per annum.Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months 0.8 0000896262 2020-01-01 2020-03-31 xbrli:shares 0000896262 2020-05-01 iso4217:USD 0000896262 2020-03-31 0000896262 2019-12-31 iso4217:USD xbrli:shares 0000896262 2019-01-01 2019-03-31 0000896262 us-gaap:CommonStockMember 2019-12-31 0000896262 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000896262 us-gaap:TreasuryStockMember 2019-12-31 0000896262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000896262 us-gaap:RetainedEarningsMember 2019-12-31 0000896262 us-gaap:NoncontrollingInterestMember 2019-12-31 0000896262 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000896262 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000896262 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0000896262 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0000896262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000896262 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000896262 us-gaap:CommonStockMember 2020-03-31 0000896262 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000896262 us-gaap:TreasuryStockMember 2020-03-31 0000896262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000896262 us-gaap:RetainedEarningsMember 2020-03-31 0000896262 us-gaap:NoncontrollingInterestMember 2020-03-31 0000896262 2018-12-31 0000896262 us-gaap:CommonStockMember 2018-12-31 0000896262 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000896262 us-gaap:TreasuryStockMember 2018-12-31 0000896262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000896262 us-gaap:RetainedEarningsMember 2018-12-31 0000896262 us-gaap:NoncontrollingInterestMember 2018-12-31 0000896262 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000896262 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000896262 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0000896262 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0000896262 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000896262 2019-03-31 0000896262 us-gaap:CommonStockMember 2019-03-31 0000896262 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000896262 us-gaap:TreasuryStockMember 2019-03-31 0000896262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000896262 us-gaap:RetainedEarningsMember 2019-03-31 0000896262 us-gaap:NoncontrollingInterestMember 2019-03-31 xbrli:pure 0000896262 amed:MedicareRevenueMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 amed:care_center 0000896262 amed:HomeHealthMember 2020-03-31 0000896262 amed:HospiceMember 2020-03-31 0000896262 amed:PersonalCareMember 2020-03-31 amed:state 0000896262 amed:MedicareRevenueMember us-gaap:RevenueFromContractWithCustomerMember 2019-01-01 2019-03-31 0000896262 amed:HomeHealthMedicareMember 2020-01-01 2020-03-31 0000896262 amed:HomeHealthMedicareMember 2019-01-01 2019-03-31 0000896262 amed:HomeHealthNonMedicareEpisodicBasedMember 2020-01-01 2020-03-31 0000896262 amed:HomeHealthNonMedicareEpisodicBasedMember 2019-01-01 2019-03-31 0000896262 amed:HomeHealthNonMedicareNonEpisodicBasedMember 2020-01-01 2020-03-31 0000896262 amed:HomeHealthNonMedicareNonEpisodicBasedMember 2019-01-01 2019-03-31 0000896262 amed:HospiceMedicareMember 2020-01-01 2020-03-31 0000896262 amed:HospiceMedicareMember 2019-01-01 2019-03-31 0000896262 amed:HospiceNonMedicareMember 2020-01-01 2020-03-31 0000896262 amed:HospiceNonMedicareMember 2019-01-01 2019-03-31 0000896262 amed:PersonalCareMember 2020-01-01 2020-03-31 0000896262 amed:PersonalCareMember 2019-01-01 2019-03-31 amed:visit 0000896262 srt:MinimumMember 2020-01-01 2020-03-31 0000896262 srt:MaximumMember 2020-01-01 2020-03-31 0000896262 amed:HomeHealthMember 2020-01-01 2020-03-31 0000896262 amed:HospiceMember 2020-01-01 2020-03-31 0000896262 amed:CapYearTwoThousandThirteenThroughTwoThousandTwentyMember 2020-03-31 0000896262 amed:CapYearTwoThousandThirteenThroughTwoThousandTwentyMember 2019-12-31 0000896262 amed:AsanaHospiceAquisitionMember 2020-03-31 0000896262 amed:COVID19PPEMember 2020-03-31 amed:day 0000896262 us-gaap:FairValueInputsLevel1Member 2020-03-31 0000896262 us-gaap:FairValueInputsLevel2Member 2020-03-31 0000896262 us-gaap:FairValueInputsLevel3Member 2020-03-31 0000896262 amed:HomeHealthMember 2020-03-01 2020-03-01 0000896262 amed:HomeHealthMember amed:CertificateOfNeedMember 2020-03-31 0000896262 amed:HospiceMember amed:AsanaHospiceMember 2020-01-01 2020-01-01 0000896262 amed:HospiceMember amed:AsanaHospiceMember 2020-03-31 0000896262 amed:HospiceMember amed:AsanaHospiceMember 2020-01-01 2020-03-31 0000896262 amed:HospiceMember amed:AsanaHospiceMember amed:MedicareLicenseMember 2020-03-31 0000896262 amed:HospiceMember amed:AsanaHospiceMember amed:AcquiredNamesOfBusinessMember 2020-03-31 0000896262 amed:HospiceMember amed:AsanaHospiceMember us-gaap:NoncompeteAgreementsMember 2020-03-31 0000896262 amed:HospiceMember amed:AsanaHospiceMember amed:AcquiredNamesOfBusinessMember 2020-01-01 2020-03-31 0000896262 amed:HospiceMember amed:AsanaHospiceMember us-gaap:NoncompeteAgreementsMember 2020-01-01 2020-03-31 0000896262 us-gaap:LoansPayableMember amed:OneHundredSeventyFiveMillionTermLoanFacilityMember 2020-03-31 0000896262 us-gaap:EurodollarMember us-gaap:LoansPayableMember amed:OneHundredSeventyFiveMillionTermLoanFacilityMember 2020-03-31 0000896262 us-gaap:LoansPayableMember amed:OneHundredSeventyFiveMillionTermLoanFacilityMember 2020-01-01 2020-03-31 0000896262 us-gaap:LoansPayableMember amed:OneHundredSeventyFiveMillionTermLoanFacilityMember 2019-12-31 0000896262 us-gaap:RevolvingCreditFacilityMember amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember 2020-03-31 0000896262 us-gaap:RevolvingCreditFacilityMember us-gaap:EurodollarMember amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember 2020-03-31 0000896262 us-gaap:RevolvingCreditFacilityMember amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember 2020-01-01 2020-03-31 0000896262 us-gaap:RevolvingCreditFacilityMember amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember 2019-12-31 0000896262 amed:PromissoryNotesMember 2020-03-31 0000896262 amed:PromissoryNotesMember 2019-12-31 0000896262 us-gaap:CapitalLeaseObligationsMember 2020-03-31 0000896262 us-gaap:CapitalLeaseObligationsMember 2019-12-31 0000896262 2019-02-04 0000896262 amed:AmendedCreditAgreementMember amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember 2019-02-04 0000896262 amed:AmendedCreditAgreementMember amed:OneHundredSeventyFiveMillionTermLoanFacilityMember 2019-02-04 0000896262 amed:AmendedCreditAgreementMember 2019-02-04 2019-02-04 0000896262 us-gaap:BaseRateMember amed:AmendedCreditAgreementMember 2020-01-01 2020-03-31 0000896262 us-gaap:EurodollarMember amed:AmendedCreditAgreementMember 2020-01-01 2020-03-31 0000896262 srt:MinimumMember amed:DebtInstrumentByLeverageRatioTrancheOneMember 2020-01-01 2020-03-31 0000896262 amed:DebtInstrumentByLeverageRatioTrancheOneMember 2020-01-01 2020-03-31 0000896262 us-gaap:EurodollarMember amed:DebtInstrumentByLeverageRatioTrancheOneMember 2020-01-01 2020-03-31 0000896262 us-gaap:BaseRateMember amed:DebtInstrumentByLeverageRatioTrancheOneMember 2020-01-01 2020-03-31 0000896262 amed:DebtInstrumentByLeverageRatioTrancheTwoMember srt:MaximumMember 2020-01-01 2020-03-31 0000896262 srt:MinimumMember amed:DebtInstrumentByLeverageRatioTrancheTwoMember 2020-01-01 2020-03-31 0000896262 amed:DebtInstrumentByLeverageRatioTrancheTwoMember 2020-01-01 2020-03-31 0000896262 amed:DebtInstrumentByLeverageRatioTrancheTwoMember us-gaap:EurodollarMember 2020-01-01 2020-03-31 0000896262 amed:DebtInstrumentByLeverageRatioTrancheTwoMember us-gaap:BaseRateMember 2020-01-01 2020-03-31 0000896262 amed:DebtInstrumentByLeverageRatioTrancheThreeMember srt:MaximumMember 2020-01-01 2020-03-31 0000896262 srt:MinimumMember amed:DebtInstrumentByLeverageRatioTrancheThreeMember 2020-01-01 2020-03-31 0000896262 amed:DebtInstrumentByLeverageRatioTrancheThreeMember 2020-01-01 2020-03-31 0000896262 us-gaap:EurodollarMember amed:DebtInstrumentByLeverageRatioTrancheThreeMember 2020-01-01 2020-03-31 0000896262 us-gaap:BaseRateMember amed:DebtInstrumentByLeverageRatioTrancheThreeMember 2020-01-01 2020-03-31 0000896262 amed:DebtInstrumentByLeverageRatioTrancheFourMember srt:MaximumMember 2020-01-01 2020-03-31 0000896262 amed:DebtInstrumentByLeverageRatioTrancheFourMember 2020-01-01 2020-03-31 0000896262 us-gaap:EurodollarMember amed:DebtInstrumentByLeverageRatioTrancheFourMember 2020-01-01 2020-03-31 0000896262 us-gaap:BaseRateMember amed:DebtInstrumentByLeverageRatioTrancheFourMember 2020-01-01 2020-03-31 0000896262 amed:AmendedCreditAgreementMember amed:OneHundredSeventyFiveMillionTermLoanFacilityMember 2019-02-04 2020-03-31 0000896262 us-gaap:SubsequentEventMember amed:AmendedCreditAgreementMember amed:OneHundredSeventyFiveMillionTermLoanFacilityMember 2020-04-01 2023-03-31 0000896262 us-gaap:SubsequentEventMember amed:AmendedCreditAgreementMember amed:OneHundredSeventyFiveMillionTermLoanFacilityMember 2023-04-01 2024-02-04 0000896262 srt:MinimumMember amed:AmendedCreditAgreementMember 2019-02-04 2019-02-04 0000896262 us-gaap:RevolvingCreditFacilityMember amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember 2019-01-01 2019-03-31 0000896262 us-gaap:LoansPayableMember amed:OneHundredSeventyFiveMillionTermLoanFacilityMember 2019-02-04 2019-03-31 0000896262 us-gaap:LineOfCreditMember amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember 2020-03-31 0000896262 amed:AmendedCreditAgreementMember us-gaap:BaseRateMember 2019-02-04 2019-02-04 0000896262 amed:AmendedCreditAgreementMember us-gaap:EurodollarMember 2019-02-04 2019-02-04 0000896262 amed:AmendedCreditAgreementMember 2019-01-01 2019-12-31 amed:patient 0000896262 stpr:MA amed:HospiceMember amed:UsDepartmentOfJusticeMember 2015-05-21 2015-05-21 0000896262 amed:HospiceMember amed:UsDepartmentOfJusticeMember amed:MorgantownWestVirginiaMember 2015-11-03 2015-11-03 0000896262 amed:HospiceMember amed:UsDepartmentOfJusticeMember amed:ParkersburgWestVirginiaMember 2016-06-27 2016-06-27 0000896262 amed:HospiceMember amed:UsDepartmentOfJusticeMember 2020-03-31 0000896262 amed:CompassionateCareHospiceCIAMember 2015-01-30 2015-01-30 0000896262 amed:AmedisysCIAMember 2014-04-23 2014-04-23 amed:beneficiary 0000896262 amed:HospiceMember stpr:SC 2008-01-01 2010-03-31 0000896262 amed:ExtrapolatedMember amed:HospiceMember stpr:SC 2011-06-06 2011-06-06 0000896262 amed:HospiceMember stpr:SC amed:UnfavorableMember 2016-01-18 amed:claim 0000896262 amed:HospiceMember stpr:SC amed:UnfavorableMember 2016-01-18 2016-01-18 0000896262 amed:HospiceMember stpr:SC amed:UnfavorableMember 2020-03-31 0000896262 amed:HospiceMember stpr:SC 2019-01-10 0000896262 amed:HospiceMember stpr:SC 2018-12-31 0000896262 amed:SafeguardZoneProgramIntegrityContractorMember amed:HomeHealthMember amed:LakelandFloridaMember 2017-08-31 0000896262 amed:SafeguardZoneProgramIntegrityContractorMember amed:HomeHealthMember amed:LakelandFloridaMember 2017-08-01 2017-08-31 0000896262 amed:SafeguardZoneProgramIntegrityContractorMember amed:HomeHealthMember amed:ClearwaterFloridaMember 2017-08-31 0000896262 amed:SafeguardZoneProgramIntegrityContractorMember amed:HomeHealthMember amed:ClearwaterFloridaMember 2017-08-01 2017-08-31 0000896262 amed:SafeguardZoneProgramIntegrityContractorMember amed:HomeHealthMember amed:LakelandFloridaMember 2020-03-31 0000896262 amed:SafeguardZoneProgramIntegrityContractorMember amed:HomeHealthMember amed:ClearwaterFloridaMember 2020-03-31 0000896262 amed:SafeguardZoneProgramIntegrityContractorMember amed:InfinityHomeCareMember stpr:FL 2017-08-31 0000896262 amed:SafeguardZoneProgramIntegrityContractorMember srt:MinimumMember amed:HomeHealthMember stpr:FL 2017-08-31 0000896262 amed:SafeguardZoneProgramIntegrityContractorMember amed:HomeHealthMember stpr:FL srt:MaximumMember 2017-08-31 0000896262 amed:SafeguardZoneProgramIntegrityContractorMember amed:HomeHealthMember stpr:FL srt:MaximumMember 2020-03-31 0000896262 amed:SafeguardZoneProgramIntegrityContractorMember stpr:FL 2020-03-31 0000896262 amed:SafeguardZoneProgramIntegrityContractorMember stpr:FL 2017-08-31 0000896262 amed:SafeguardZoneProgramIntegrityContractorMember amed:HomeHealthMember stpr:FL 2017-01-01 2017-12-31 0000896262 amed:SafeguardZoneProgramIntegrityContractorMember amed:InfinityHomeCareMember amed:HomeHealthMember stpr:FL 2020-03-31 amed:Segments 0000896262 amed:PersonalCareMember 2020-01-01 2020-03-31 0000896262 us-gaap:AllOtherSegmentsMember 2020-01-01 2020-03-31 0000896262 amed:HomeHealthMember 2019-01-01 2019-03-31 0000896262 amed:HospiceMember 2019-01-01 2019-03-31 0000896262 amed:PersonalCareMember 2019-01-01 2019-03-31 0000896262 us-gaap:AllOtherSegmentsMember 2019-01-01 2019-03-31 0000896262 2019-02-25 0000896262 2019-02-25 2019-02-25 0000896262 amed:MedalogixMember 2018-01-01 2018-12-31 0000896262 amed:MedalogixMember 2020-01-01 2020-03-31 0000896262 2020-03-27 0000896262 us-gaap:SubsequentEventMember 2020-04-01 2020-04-30 0000896262 us-gaap:SubsequentEventMember 2020-04-24 0000896262 us-gaap:SubsequentEventMember amed:AseraCareHospiceMember 2020-04-23 2020-04-23

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

FORM 10-Q

(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2020
or

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to
Commission File Number: 0-24260

AMEDISYS, INC.
(Exact Name of Registrant as Specified in its Charter)

Delaware |  | 11-3131700
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)

3854 American Way, Suite A, Baton Rouge, LA 70816
(Address of principal executive offices, including zip code)
(225) 292-2031 or (800) 467-2662
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, par value $0.001 per share |  | AMED |  | The NASDAQ Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer |  | ☒ |  | Accelerated filer |  | ☐
Non-accelerated filer |  | ☐ |  | Smaller reporting company |  | ☐
Emerging growth company |  | ☐ |  |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date, is as follows: Common stock, $0.001 par value, 32,379,165 shares outstanding as of May 1, 2020.

TABLE OF CONTENTS

SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS |  | 1
;;; |  |
PART I. | FINANCIAL INFORMATION |
ITEM 1. | FINANCIAL STATEMENTS: |
| CONDENSED CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2020 (UNAUDITED) AND DECEMBER 31, 2019 | 2
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2020 AND 2019 (UNAUDITED) | 3
| CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2020 AND 2019 (UNAUDITED) | 4
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2020 AND 2019 (UNAUDITED) | 5
ITEM 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 21
ITEM 3 | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 31
ITEM 4. | CONTROLS AND PROCEDURES | 31
PART II. OTHER INFORMATION |  |
ITEM 1. | LEGAL PROCEEDINGS | 33
ITEM 1A. | RISK FACTORS | 33
ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | 33
ITEM 3. | DEFAULTS UPON SENIOR SECURITIES | 33
ITEM 4. | MINE SAFETY DISCLOSURES | 33
ITEM 5. | OTHER INFORMATION | 33
ITEM 6. | EXHIBITS | 34
SIGNATURES |  | 35

SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS
When included in this Quarterly Report on Form 10-Q, or in other documents that we file with the Securities and Exchange Commission (“SEC”) or in statements made by or on behalf of the Company, words like “believes,” “belief,” “expects,” “strategy,”“plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “could,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic ("COVID-19"), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, competition in the healthcare industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to consistently provide high-quality care, our ability to attract and retain qualified personnel, our ability to keep our patients and employees safe, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disaster or acts of terrorism, our ability to integrate, manage and keep our information systems secure, our ability to realize the anticipated benefits of acquisitions, and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law. For a discussion of some of the factors discussed above as well as additional factors, see our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 19, 2020, particularly, Part I, Item 1A - Risk Factors therein, which are incorporated herein by reference and Part II, Item 1A. Risk Factors of this Quarterly Report on Form 10-Q. Additional risk factors may also be described in reports that we file from time to time with the SEC.
Available Information
Our company website address is www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website. In addition, we make available on the Investor Relations subpage of our website (under the link “SEC filings”), free of charge, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as reasonably practicable after we electronically file or furnish such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct, our Corporate Governance Guidelines and the charters for the Audit, Compensation, Quality of Care, Compliance and Ethics and Nominating and Corporate Governance Committees of our Board are also available on the Investor Relations subpage of our website (under the link “Governance”). Reference to our website does not constitute incorporation by reference of the information contained on the website and should not be considered part of this document. Our electronically filed reports can also be obtained on the SEC’s internet site at http://www.sec.gov.
1

PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share data)

| March 31, 2020 (unaudited) |  | December 31, 2019
ASSETS |  |  |
Current assets: |  |  |
Cash and cash equivalents | $ | 174,756 |  |  | $ | 30,294 |
Restricted cash | 3,056 |  |  | 66,196 |
Patient accounts receivable | 268,551 |  |  | 237,596 |
Prepaid expenses | 12,487 |  |  | 8,243 |
Other current assets | 9,278 |  |  | 8,225 |
Total current assets | 468,128 |  |  | 350,554 |
Property and equipment, net of accumulated depreciation of $98,472 and $96,137 | 26,477 |  |  | 28,113 |
Operating lease right of use assets | 83,693 |  |  | 84,791 |
Goodwill | 721,049 |  |  | 658,500 |
Intangible assets, net of accumulated amortization of $9,341 and $7,044 | 68,251 |  |  | 64,748 |
Deferred income taxes | 20,199 |  |  | 21,427 |
Other assets | 52,287 |  |  | 54,612 |
Total assets | $ | 1,440,084 |  |  | $ | 1,262,745 |
LIABILITIES AND EQUITY |  |  |
Current liabilities: |  |  |
Accounts payable | $ | 31,147 |  |  | $ | 31,259 |
Payroll and employee benefits | 109,713 |  |  | 120,877 |
Accrued expenses | 136,659 |  |  | 137,111 |
Current portion of long-term obligations | 11,122 |  |  | 9,927 |
Current portion of operating lease liabilities | 27,465 |  |  | 27,769 |
Total current liabilities | 316,106 |  |  | 326,943 |
Long-term obligations, less current portion | 379,942 |  |  | 232,256 |
Operating lease liabilities, less current portion | 54,926 |  |  | 56,128 |
Other long-term obligations | 8,966 |  |  | 5,905 |
Total liabilities | 759,940 |  |  | 621,232 |
Commitments and Contingencies—Note 5 |  |  |
Equity: |  |  |
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding | — |  |  | — |
Common stock, $0.001 par value, 60,000,000 shares authorized; 36,746,554 and 36,638,021 shares issued; and 32,370,345 and 32,284,051 shares outstanding | 37 |  |  | 37 |
Additional paid-in capital | 656,266 |  |  | 645,256 |
Treasury stock, at cost 4,376,209 and 4,353,970 shares of common stock | (255,291) |  |  | (251,241) |
Accumulated other comprehensive income | — |  |  | 15 |
Retained earnings | 278,185 |  |  | 246,383 |
Total Amedisys, Inc. stockholders’ equity | 679,197 |  |  | 640,450 |
Noncontrolling interests | 947 |  |  | 1,063 |
Total equity | 680,144 |  |  | 641,513 |
Total liabilities and equity | $ | 1,440,084 |  |  | $ | 1,262,745 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
2

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except per share data)
(Unaudited)

| For the Three-Month Periods Ended March 31, |  |
| 2020 |  | 2019
Net service revenue | $ | 491,685 |  |  | $ | 467,340 |
Cost of service, excluding depreciation and amortization | 285,737 |  |  | 275,274 |
General and administrative expenses: |  |  |
Salaries and benefits | 101,566 |  |  | 94,830 |
Non-cash compensation | 5,909 |  |  | 6,615 |
Other | 49,265 |  |  | 43,402 |
Depreciation and amortization | 5,338 |  |  | 2,895 |
Operating expenses | 447,815 |  |  | 423,016 |
Operating income | 43,870 |  |  | 44,324 |
Other income (expense): |  |  |
Interest income | 13 |  |  | 24 |
Interest expense | (3,231) |  |  | (3,349) |
Equity in earnings from equity method investments | 477 |  |  | 1,216 |
Miscellaneous, net | 263 |  |  | 236 |
Total other expense, net | (2,478) |  |  | (1,873) |
Income before income taxes | 41,392 |  |  | 42,451 |
Income tax expense | (9,346) |  |  | (10,878) |
Net income | 32,046 |  |  | 31,573 |
Net income attributable to noncontrolling interests | (244) |  |  | (269) |
Net income attributable to Amedisys, Inc. | $ | 31,802 |  |  | $ | 31,304 |
Basic earnings per common share: |  |  |
Net income attributable to Amedisys, Inc. common stockholders | $ | 0.98 |  |  | $ | 0.98 |
Weighted average shares outstanding | 32,331 |  |  | 32,001 |
Diluted earnings per common share: |  |  |
Net income attributable to Amedisys, Inc. common stockholders | $ | 0.96 |  |  | $ | 0.95 |
Weighted average shares outstanding | 33,234 |  |  | 32,893 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
3

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Amounts in thousands, except common stock shares)
(Unaudited)

| For the Three-Months Ended March 31, 2020 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Total |  | Common Stock |  |  |  | Additional Paid-in Capital |  | Treasury Stock |  | Accumulated Other Comprehensive Income |  | Retained Earnings |  | Noncontrolling Interests
|  |  | Shares |  | Amount |  |  |  |  |  |  |  |  |  |
Balance, December 31, 2019 | $ | 641,513 |  |  | 36,638,021 |  |  | $ | 37 |  |  | $ | 645,256 |  |  | $ | (251,241) |  |  | $ | 15 |  |  | $ | 246,383 |  |  | $ | 1,063 |
Issuance of stock – employee stock purchase plan | 860 |  |  | 6,063 |  |  | — |  |  | 860 |  |  | — |  |  | — |  |  | — |  |  | — |
Issuance of stock – 401(k) plan | 3,057 |  |  | 18,312 |  |  | — |  |  | 3,057 |  |  | — |  |  | — |  |  | — |  |  | — |
Issuance/(cancellation) of non-vested stock | — |  |  | 55,423 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Exercise of stock options | 1,184 |  |  | 28,735 |  |  | — |  |  | 1,184 |  |  | — |  |  | — |  |  | — |  |  | — |
Non-cash compensation | 5,909 |  |  | — |  |  | — |  |  | 5,909 |  |  | — |  |  | — |  |  | — |  |  | — |
Surrendered shares | (4,050) |  |  | — |  |  | — |  |  | — |  |  | (4,050) |  |  | — |  |  | — |  |  | — |
Noncontrolling interest distribution | (360) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (360) |
Write-off of other comprehensive income | (15) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (15) |  |  | — |  |  | — |
Net income | 32,046 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 31,802 |  |  | 244 |
Balance, March 31, 2020 | $ | 680,144 |  |  | 36,746,554 |  |  | $ | 37 |  |  | $ | 656,266 |  |  | $ | (255,291) |  |  | $ | — |  |  | $ | 278,185 |  |  | $ | 947 |
| For the Three-Months Ended March 31, 2019 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Total |  | Common Stock |  |  |  | Additional Paid-in Capital |  | Treasury Stock |  | Accumulated Other Comprehensive Income |  | Retained Earnings |  | Noncontrolling Interests
|  |  | Shares |  | Amount |  |  |  |  |  |  |  |  |  |
Balance, December 31, 2018 | $ | 482,633 |  |  | 36,252,280 |  |  | $ | 36 |  |  | $ | 603,666 |  |  | $ | (241,685) |  |  | $ | 15 |  |  | $ | 119,550 |  |  | $ | 1,051 |
Issuance of stock – employee stock purchase plan | 782 |  |  | 7,856 |  |  | — |  |  | 782 |  |  | — |  |  | — |  |  | — |  |  | — |
Issuance of stock – 401(k) plan | 2,295 |  |  | 19,591 |  |  | — |  |  | 2,295 |  |  | — |  |  | — |  |  | — |  |  | — |
Issuance/(cancellation) of non-vested stock | — |  |  | 51,162 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Exercise of stock options | 356 |  |  | 6,854 |  |  | — |  |  | 356 |  |  | — |  |  | — |  |  | — |  |  | — |
Non-cash compensation | 6,615 |  |  | — |  |  | — |  |  | 6,615 |  |  | — |  |  | — |  |  | — |  |  | — |
Surrendered shares | (2,688) |  |  | — |  |  | — |  |  | — |  |  | (2,688) |  |  | — |  |  | — |  |  | — |
Noncontrolling interest distribution | (366) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (366) |
Net income | 31,573 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 31,304 |  |  | 269 |
Balance, March 31, 2019 | $ | 521,200 |  |  | 36,337,743 |  |  | $ | 36 |  |  | $ | 613,714 |  |  | $ | (244,373) |  |  | $ | 15 |  |  | $ | 150,854 |  |  | $ | 954 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
4

AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
(Unaudited)

| For the Three-Month Periods Ended March 31, |  |
| 2020 |  | 2019
Cash Flows from Operating Activities: |  |  |
Net income | $ | 32,046 |  |  | $ | 31,573 |
Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
Depreciation and amortization | 5,338 |  |  | 2,895 |
Non-cash compensation | 5,909 |  |  | 6,615 |
401(k) employer match | 3,291 |  |  | 2,379 |
Amortization and impairment of operating lease right of use assets | 9,058 |  |  | 8,345 |
Loss (gain) on disposal of property and equipment | 55 |  |  | (4) |
Write-off of other comprehensive income | (15) |  |  | — |
Deferred income taxes | 1,228 |  |  | 3,269 |
Equity in earnings from equity method investments | (477) |  |  | (1,216) |
Amortization of deferred debt issuance costs/debt discount | 220 |  |  | 213 |
Return on equity investment | 2,369 |  |  | 725 |
Changes in operating assets and liabilities, net of impact of acquisitions: |  |  |
Patient accounts receivable | (25,459) |  |  | (22,333) |
Other current assets | (5,756) |  |  | (10,635) |
Other assets | 417 |  |  | (338) |
Accounts payable | (2,673) |  |  | (11,140) |
Accrued expenses | (13,627) |  |  | 18,838 |
Other long-term obligations | 3,060 |  |  | (144) |
Operating lease liabilities | (8,132) |  |  | (8,139) |
Operating lease right of use assets | (817) |  |  | (844) |
Net cash provided by operating activities | 6,035 |  |  | 20,059 |
Cash Flows from Investing Activities: |  |  |
Proceeds from sale of deferred compensation plan assets | 16 |  |  | 208 |
Proceeds from the sale of property and equipment | 12 |  |  | 65 |
Purchases of property and equipment | (1,434) |  |  | (1,198) |
Investments in equity method investees | — |  |  | (120) |
Acquisitions of businesses, net of cash acquired | (69,349) |  |  | (327,867) |
Net cash used in investing activities | (70,755) |  |  | (328,912) |
Cash Flows from Financing Activities: |  |  |
Proceeds from issuance of stock upon exercise of stock options | 1,184 |  |  | 356 |
Proceeds from issuance of stock to employee stock purchase plan | 860 |  |  | 782 |
Shares withheld upon stock vesting | (4,050) |  |  | (2,688) |
Noncontrolling interest distribution | (360) |  |  | (366) |
Proceeds from borrowings under term loan | — |  |  | 175,000 |
Proceeds from borrowings under revolving line of credit | 187,500 |  |  | 161,500 |
Repayments of borrowings under revolving line of credit | (37,500) |  |  | (34,000) |
Principal payments of long-term obligations | (1,592) |  |  | (559) |
Debt issuance costs | — |  |  | (847) |
Net cash provided by financing activities | 146,042 |  |  | 299,178 |
Net increase (decrease) in cash, cash equivalents and restricted cash | 81,322 |  |  | (9,675) |
Cash, cash equivalents and restricted cash at beginning of period | 96,490 |  |  | 20,229 |
Cash, cash equivalents and restricted cash at end of period | $ | 177,812 |  |  | $ | 10,554 |
Supplemental Disclosures of Cash Flow Information: |  |  |
Cash paid for interest | $ | 1,755 |  |  | $ | 725 |
Cash paid for income taxes, net of refunds received | $ | 5,272 |  |  | $ | 404 |
Cash paid for operating lease liabilities | $ | 8,949 |  |  | $ | 8,983 |
Cash paid for finance lease liabilities | $ | 499 |  |  | $ | 384 |
Supplemental Disclosures of Non-Cash Activity: |  |  |
Right of use assets obtained in exchange for operating lease liabilities | $ | 6,437 |  |  |  | $ | 91,743 |
Right of use assets obtained in exchange for finance lease liabilities | $ | 254 |  |  |  | $ | 808 |
Reductions to right of use assets resulting from reductions to operating lease liabilities | $ | 159 |  |  |  | $ | 625 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
6

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS
Amedisys, Inc., a Delaware corporation, (together with its consolidated subsidiaries, referred to herein as “Amedisys,” “we,” “us,” or “our”) is a multi-state provider of home health, hospice and personal care services with approximately 74% of our revenue derived from Medicare for the three-month periods ended March 31, 2020 and 2019. As of March 31, 2020, we owned and operated 322 Medicare-certified home health care centers, 146 Medicare-certified hospice care centers and 12 personal-care care centers in 38 states within the United States and the District of Columbia.
Basis of Presentation
In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations, and our cash flows in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.
This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (“SEC”) on February 19, 2020 (the “Form 10-K”), which includes information and disclosures not included herein. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations.
Recently Issued Accounting Pronouncements
In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and improves consistent application by clarifying and amending existing guidance. The ASU is effective for annual and interim periods beginning after December 15, 2020. Early adoption is permitted. While the Company does not expect a material impact upon adoption of ASU 2019-12, we are still evaluating the effect the standard will have on our consolidated financial statements and related disclosures and ongoing financial reporting.
Use of Estimates
Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
Principles of Consolidation
These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying unaudited condensed consolidated financial statements, and business combinations accounted for as purchases have been included in our unaudited condensed consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.
Investments
We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements.
We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary.
7

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
The book value of investments that we account for under the equity method of accounting was $33.8 million and $35.7 million as of March 31, 2020 and December 31, 2019, respectively, and is reflected in other assets within our condensed consolidated balance sheets.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Revenue Recognition
We account for revenue from contracts with customers in accordance with ASU 2014-09, Revenue from Contracts with Customers (Topic 606) and ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date (collectively, "ASC 606"), and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material.
Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals.
The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.
We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments include adjustments provided to patients and third-party payors. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change.
Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third party payors and others for services provided.
Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 74% of the Company's consolidated net service revenue for the three-month periods ended March 31, 2020 and 2019.
Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.
We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.
8

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Revenue by payor class as a percentage of total net service revenue is as follows:

| For the Three-Month Periods Ended March 31, |  |
| 2020 |  | 2019
Home Health: |  |  |
Medicare | 41 | % |  | 46 | %
Non-Medicare - Episodic-based | 6 | % |  | 9 | %
Non-Medicare - Non-episodic based | 14 | % |  | 12 | %
Hospice (1): |  |  |
Medicare | 33 | % |  | 28 | %
Non-Medicare | 2 | % |  | 1 | %
Personal Care | 4 | % |  | 4 | %
| 100 | % |  | 100 | %
(1) Acquired Compassionate Care Hospice on February 1, 2019, RoseRock Healthcare on April 1, 2019 and Asana Hospice on January 1, 2020. |  |  |  |

Home Health Revenue Recognition
Medicare Revenue
Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.
Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care ("billing period"). PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b) a low utilization payment adjustment (“LUPA”) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c) a partial payment if a patient transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payment for non-routine supplies are now included in the 30-day payment rate.
Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered as a reduction to revenue and a corresponding reduction to patient accounts receivable.
Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.
The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave their home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS has relaxed the definition of homebound status. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit.
9

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprising of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed.
As noted above, under PDGM, we are now reimbursed for 30-day periods of care rather than 60-day episodes of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity’s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice” practical expedient utilizing our historical average length of stay for each 30-day payment period as the measure of progress towards the satisfaction of our performance obligation.
A portion of reimbursement from each Medicare episode is billed near the start of each 30-day period of care, and cash is typically received before all services are rendered. The amount of revenue recognized for periods of care which are incomplete at period end is based on the company's historical average percentage of days complete on each 30-day period of care. Any cash received from Medicare for a request for anticipated payment (“RAP”) for a 30-day period of care that exceeds the associated revenue earned is recorded to accrued expenses within our condensed consolidated balance sheets.
Non-Medicare Revenue
Episodic-based Revenue. We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms which generally range from 90% to 100% of Medicare rates.
Non-episodic based Revenue. Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on historical experience, to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.
Hospice Revenue Recognition
Hospice Medicare Revenue
Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% and 98% of our total net Medicare hospice service revenue for each of the three-month periods ended March 31, 2020 and March 31, 2019, respectively. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (“SIA”). The SIA is based on visits made in the last seven days of life by a registered nurse (“RN”) or medical social worker (“MSW”) for patients in a routine level of care.
The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.
We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.
Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded. We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheet. Beginning for the cap year ending October 31, 2017, providers are required to self-report
10

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
and pay their estimated cap liability by February 28 th of the following year. As of March 31, 2020, we have recorded $5.5 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October 31, 2013 through September 30, 2020. As of December 31, 2019, we had recorded $5.7 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October 31, 2013 through September 30, 2020.
Hospice Non-Medicare Revenue
Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on historical experience, to reflect the estimated transaction price.
Personal Care Revenue Recognition
Personal Care Revenue
We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points (ASAPs), Senior Care Options (SCOs), Program of All-Inclusive Care for the Elderly (PACE) and the Veterans Administration (VA).
Cash, Cash Equivalents and Restricted Cash
Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use. As of March 31, 2020, we had $3.1 million of restricted cash that was placed into escrow accounts related to the potential indemnity and working capital adjustment provisions within the Asana Hospice purchase agreement ($2.3 million) and to secure the purchase of personal protective equipment from new suppliers in response to COVID-19 ($0.8 million).
Patient Accounts Receivable
We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. As of March 31, 2020, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectibility risk associated with our Medicare accounts, which represent 58% of our patient accounts receivable at March 31, 2020 and December 31, 2019 is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor.
We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.
Medicare Home Health
For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for 20% of our estimated payment for each 30-day period of care. The full amount of the payment for each 30-day period of care is billed after the period of care has been completed (“final billed”). The RAP received for that billing period is then deducted from our final payment. If a final bill is not submitted within the greater of 90 days from the start of the 30-day period of care, or 60 days from the date the RAP was paid,
11

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
any RAPs received for that billing period will be recouped by Medicare from any other claims in process for that particular provider number. The RAP claim must then be resubmitted. CMS has mandated the full elimination of RAPs in 2021.
Medicare Hospice
For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.
Non-Medicare Home Health, Hospice and Personal Care
For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient’s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.
Fair Value of Financial Instruments
The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):

| Fair Value at Reporting Date Using |  |  |  |  |  |
Financial Instrument | Carrying Value as of March 31, 2020 |  | Quoted Prices in Active Markets for Identical Items (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3)
Long-term obligations | $ | 391.2 |  |  | $ | — |  |  | $ | 383.6 |  |  | $ | — |

The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:
•Level 1 – Quoted prices in active markets for identical assets and liabilities.
•Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•Level 3 – Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.
Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.
12

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Weighted-Average Shares Outstanding
Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):

| For the Three- Month Periods Ended March 31, |  |
| 2020 |  | 2019
Weighted average number of shares outstanding - basic | 32,331 |  |  | 32,001 |
Effect of dilutive securities: |  |  |
Stock options | 594 |  |  | 559 |
Non-vested stock and stock units | 309 |  |  | 333 |
Weighted average number of shares outstanding - diluted | 33,234 |  |  | 32,893 |
Anti-dilutive securities | 57 |  |  | 148 |

Business Combinations
We account for acquisitions using the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets.
3. ACQUISITIONS
We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice and personal care services. The purchase price paid for acquisitions is negotiated through arm’s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.
Home Health Division
On March 1, 2020, we acquired the regulatory assets of a home health provider in Washington for a purchase price of $3.0 million. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of $2.8 million and other intangibles (certificate of need) of $0.2 million in connection with the acquisition.
Hospice Division
On January 1, 2020, we acquired Asana Hospice ("Asana"), a hospice provider with locations in Pennsylvania, Ohio, Texas, Missouri and Kansas for a purchase price of $66.3 million, net of cash acquired of $0.7 million.
The Company is in the process of finalizing its valuation of the assets acquired and liabilities assumed. Based on the Company's preliminary valuation, the total estimated consideration of $66.3 million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):
13

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

| Amount
Patient accounts receivable | $ | 5.5 |
Property and equipment | 0.2 |
Operating lease right of use assets | 0.9 |
Intangible assets | 5.6 |
Total assets acquired | 12.2 |
Accounts payable | (3.0) |
Payroll and employee benefits | (1.5) |
Accrued expenses | (0.2) |
Operating lease liabilities | (0.9) |
Total liabilities assumed | (5.6) |
Net identifiable assets acquired | 6.6 |
Goodwill | 59.7 |
Total estimated consideration | $ | 66.3 |

Intangible assets acquired include licenses ($2.0 million), acquired names ($1.3 million) and non-compete agreements ($2.3 million). The acquired names and non-compete agreements will be amortized over a weighted-average period of 2.0 years.
Asana contributed approximately $7.4 million in net service revenue and an operating loss of $1.3 million (inclusive of acquisition and integration costs totaling $1.1 million and intangibles amortization totaling $0.5 million) during the three-month period ended March 31, 2020.
4. LONG-TERM OBLIGATIONS
Long-term debt consisted of the following for the periods indicated (amounts in millions):

| March 31, 2020 |  | December 31, 2019
$175.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (2.5% at March 31, 2020); due February 4, 2024 | $ | 170.6 |  |  | $ | 171.7 |
$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (2.4% at March 31, 2020); due February 4, 2024 | 220.0 |  |  | 70.0 |
Promissory notes | 0.6 |  |  | 0.6 |
Finance leases | 3.1 |  |  | 3.4 |
Principal amount of long-term obligations | 394.3 |  |  | 245.7 |
Deferred debt issuance costs | (3.3) |  |  | (3.5) |
| 391.0 |  |  | 242.2 |
Current portion of long-term obligations | (11.1) |  |  | (9.9) |
Total | $ | 379.9 |  |  | $ | 232.3 |

14

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
First Amendment to Amended and Restated Credit Agreement
On February 4, 2019, we entered into the First Amendment to our Credit Agreement (as amended by the First Amendment, the "Amended Credit Agreement"). The Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $725.0 million, which includes a $550.0 million Revolving Credit Facility under the Credit Agreement and a term loan facility with a principal amount of up to $175.0 million (the "Term Loan Facility" and collectively with the Revolving Credit Facility, the "Credit Facility"), which was added by the First Amendment.
We borrowed the entire principal amount of the Term Loan Facility on February 4, 2019 in order to fund a portion of the purchase price of the Compassionate Care Hospice ("CCH") acquisition, with the remainder of the purchase price and associated transactional fees and expenses funded by proceeds from the Revolving Credit Facility.
The loans issued under the Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The “Base Rate” means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate plus 1% per annum. The “Eurodollar Rate” means the quoted rate per annum equal to the London Interbank Offered Rate (“LIBOR”) or a comparable successor rate approved by the Administrative Agent for an interest period of one, two, three or six months (as selected by us). The “Applicable Rate” is based on the consolidated leverage ratio and is presented in the table below. As of March 31, 2020, the Applicable Rate is 0.50% per annum for Base Rate loans and 1.50% per annum for Eurodollar Rate loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Amended Credit Agreement, as presented in the table below.

Pricing Tier | Consolidated Leverage Ratio | Commitment Fee | Letter of Credit Fee | Eurodollar Rate Loans | Base Rate Loans
I | ≥ 3.00 to 1.0 | 0.35% | 1.75% | 2.00% | 1.00%
II | < 3.00 to 1.0 but ≥ 2.00 to 1.0 | 0.30% | 1.50% | 1.75% | 0.75%
III | < 2.00 to 1.0 but ≥ 0.75 to 1.0 | 0.25% | 1.25% | 1.50% | 0.50%
IV | < 0.75 to 1.0 | 0.20% | 1.00% | 1.25% | 0.25%

The final maturity date of the Credit Facility is February 4, 2024. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) 0.625% for the period commencing on February 4, 2019 and ending on March 31, 2020, (ii) 1.250% for the period commencing on April 1, 2020 and ending on March 31, 2023, and (iii) 1.875% for the period commencing on April 1, 2023 and ending on February 4, 2024. The remaining balance of the Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Term Loan Facility, first, and the Revolving Credit Facility, second, with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $5 million or (b) any debt issuance that is not permitted under the Amended Credit Agreement.
The Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments, and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Amended Credit Agreement. In connection with our entry into the Amended Credit Agreement, we recorded $0.8 million in deferred debt issuance costs as long-term obligations, less current portion within our condensed consolidated balance sheet during the year ended December 31, 2019.
The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the
15

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions.
Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 3.2% and 4.2% for the three-month periods ended March 31, 2020 and March 31, 2019, respectively. Our weighted average interest rate for borrowings under our $175.0 million Term Loan Facility was 3.2% for the three-month period ended March 31, 2020 and 4.2% for the period February 4, 2019 to March 31, 2019.
As of March 31, 2020, our consolidated leverage ratio was 1.5, our consolidated interest coverage ratio was 16.6 and we are in compliance with our covenants under the Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.
As of March 31, 2020, our availability under our $550.0 million Revolving Credit Facility was $299.8 million as we have $220.0 million outstanding in borrowings and $30.2 million outstanding in letters of credit.
Joinder Agreement
In connection with the CCH acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019, pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement, the Amended and Restated Security Agreement, dated as of June 29, 2018, and the Amended and Restated Pledge Agreement, dated as of June 29, 2018. Pursuant to the Joinder, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries also guaranteed our obligations, whether now existing or arising after the effective date of the Joinder, under the Amended Credit Agreement pursuant to the terms of the Joinder and the Amended Credit Agreement.
5. COMMITMENTS AND CONTINGENCIES
Legal Proceedings - Ongoing
We are involved in the following legal actions:
Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice
On May 21, 2015, we received a Subpoena Duces Tecum (“Subpoena”) issued by the U.S. Department of Justice. The Subpoena requests the delivery of information regarding 53 identified hospice patients to the United States Attorney’s Office for the District of Massachusetts. It also requests the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covers the period from January 1, 2011 through May 21, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation.
On November 3, 2015, we received a civil investigative demand (“CID”) issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requests the delivery of information to the United States Attorney’s Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covers the period from January 1, 2009 through August 31, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation.
On June 27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requests the delivery of information to the United States Attorney’s Office for the Southern District of West Virginia regarding 68 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covers the period from January 1, 2011 through June 20, 2016. We are fully cooperating with the U.S. Department of Justice with respect to this investigation.
16

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Based on our analysis of sample claims data in connection with preliminary settlement discussions with the U.S. Department of Justice regarding the above matters, we have recorded a total of $6.5 million to accrued expenses in our condensed consolidated balance sheet related to this matter. Due to the ongoing nature of the investigations and current stage of the settlement discussions, we are unable to estimate a range of potential loss at this time, and we cannot predict the timing or outcome of these investigations.
In addition to the matters referenced in this note, we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.
Legal fees related to all legal matters are expensed as incurred.
Other Investigative Matters - Ongoing
Compassionate Care Hospice Corporate Integrity Agreement
On January 30, 2015, CCH entered into a corporate integrity agreement ("CIA") with the Office of Inspector General-HHS (“OIG”). The CIA required that CCH provide annual on-site compliance training; develop and implement policies to ensure compliance with federal health care program requirements; screen new and current employees to ensure that they are eligible to participate in federal health care programs; establish a compliance committee that contains both a Compliance Officer and a Chief Quality Officer; retain a Governing Authority expert who will periodically complete a compliance program review; and retain an independent review organization ("IRO") to complete claims reviews for hospice services rendered in New York. The OIG waived the claims review for the final year of the CCH CIA based on the closure of the New York operations. Additionally, the CIA required that CCH report substantial overpayments that CCH discovered it had received from federal health care programs, as well as probable violations of federal criminal, civil or administrative health care laws. Upon breach of the CIA, CCH could have become liable for payment of certain stipulated penalties, or could have been excluded from participation in federal health care programs. The CIA had a term of five years that ended on January 30, 2020. We filed our final annual report on March 25, 2020.
Other Investigative Matters - Completed
Corporate Integrity Agreement
On April 23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the U.S. Department of Justice relating to certain of our clinical and business operations. Concurrently with our entry into this agreement, we entered into a CIA with the OIG. The CIA formalized various aspects of our already existing ethics and compliance programs and contained other requirements designed to help ensure our ongoing compliance with federal health care program requirements. Among other things, the CIA required us to maintain our existing compliance program, executive compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue screening new and current employees to ensure they are eligible to participate in federal health care programs; engage an IRO to perform certain auditing and reviews and prepare certain reports regarding our compliance with federal health care programs, our billing submissions to federal health care programs and our compliance and risk mitigation programs; and provide certain reports and management certifications to the OIG. Additionally, the CIA specifically required that we report substantial overpayments that we discovered we had received from federal health care programs, as well as probable violations of federal health care laws. The corporate integrity agreement had a term of five years that ended on April 21, 2019. We filed our final annual report on July 19, 2019. On May 5, 2020, the Company received notice from the OIG that the Company's five-year CIA with the OIG has been completed.
Third Party Audits - Ongoing
From time to time, in the ordinary course of business, we are subject to audits under various governmental programs including Recovery Audit Contractors (“RACs”), Zone Program Integrity Contractors (“ZPICs”), Uniform Program Integrity Contractors ("UPICs"), Program Safeguard Contractors (“PSCs”) and Medicaid Integrity Contributors (“MICs”) in which third party firms engaged by CMS conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.
17

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January 1, 2008 through March 31, 2010 (the “Review Period”) to determine whether the underlying services met pertinent Medicare payment requirements. We acquired the hospice operations subject to this review on August 1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations. Based on the ZPIC’s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June 6, 2011, the Medicare Administrative Contractor (“MAC”) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January 18, 2016, we received a letter dated January 6, 2016 referencing the ALJ hearing decision for the overpayment issued on June 6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million, including interest, based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid. No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of March 31, 2020, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August 1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $2.8 million. Accordingly, the Company reduced its indemnity receivable from $4.9 million to $2.8 million.
In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (“SafeGuard”), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December 31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters are based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $34.0 million for the Lakeland Care Centers on a universe of 72 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate and an overpayment of $4.8 million for the Clearwater Care Center on a universe of 70 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate.
The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers has been reduced to $26.0 million and the alleged overpayment for the Clearwater Care Center has been reduced to $3.3 million. The Company has now filed Level III Administrative Appeals, and will continue to vigorously pursue its appeal rights, which include contesting the methodology used by the ZPIC contractor to perform statistical extrapolation. The Company is contractually entitled to indemnification by the prior owners for all claims prior to December 31, 2015, for up to $12.6 million.
At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing or outcome of this review. The Company estimates a low-end potential range of loss related to this review of $6.5 million (assuming the Company is successful in seeking indemnity from the prior owners and unsuccessful in demonstrating that the extrapolation method used by SafeGuard was erroneous). The Company has reduced its high-end potential range of loss from $38.8 million (the maximum amount Palmetto claims has been overpaid for both the Lakeland Care Centers and the Clearwater Care Center, of which amount $12.6 million is subject to indemnification by the prior owners) to $29.3 million based on the partial success achieved by the Company in prosecuting its Level I and II Administrative Appeals.
As of March 31, 2020, we have an accrued liability of approximately $17.4 million related to this matter. We expect to be indemnified by the prior owners for approximately $10.9 million of the total $12.6 million available indemnification related to this matter and have recorded this amount within other assets in our condensed consolidated balance sheet as of March 31, 2020. The net of these two amounts, $6.5 million, was recorded as a reduction in revenue in our condensed consolidated statements of operations during 2017. As of March 31, 2020, $1.5 million of receivables have been impacted by this payment suspension.
18

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Insurance
We are obligated for certain costs associated with our insurance programs, including employee health, workers’ compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.
Our health insurance has an exposure limit of $1.3 million for any individual covered life. Our workers’ compensation insurance has a retention limit of $1.0 million per incident and our professional liability insurance has a retention limit of $0.3 million per incident.
6. SEGMENT INFORMATION
Our operations involve servicing patients through our three reportable business segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. The “other” column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.
Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company’s chief operating decision maker and therefore are not disclosed below (amounts in millions).

| For the Three-Month Period Ended March 31, 2020 |  |  |  |  |  |  |  |
| Home Health |  | Hospice |  | Personal Care |  | Other |  | Total
Net service revenue | $ | 303.6 |  |  | $ | 169.4 |  |  | $ | 18.7 |  |  | $ | — |  |  | $ | 491.7 |
Cost of service, excluding depreciation and amortization | 179.8 |  |  | 91.8 |  |  | 14.1 |  |  | — |  |  | 285.7 |
General and administrative expenses | 75.7 |  |  | 38.7 |  |  | 3.4 |  |  | 39.0 |  |  | 156.8 |
Depreciation and amortization | 1.0 |  |  | 0.6 |  |  | — |  |  | 3.7 |  |  | 5.3 |
Operating expenses | 256.5 |  |  | 131.1 |  |  | 17.5 |  |  | 42.7 |  |  | 447.8 |
Operating income (loss) | $ | 47.1 |  |  | $ | 38.3 |  |  | $ | 1.2 |  |  | $ | (42.7) |  |  | $ | 43.9 |
| For the Three-Month Period Ended March 31, 2019 |  |  |  |  |  |  |  |
| Home Health |  | Hospice |  | Personal Care |  | Other |  | Total
Net service revenue | $ | 310.1 |  |  | $ | 137.0 |  |  | $ | 20.2 |  |  | $ | — |  |  | $ | 467.3 |
Cost of service, excluding depreciation and amortization | 185.7 |  |  | 74.1 |  |  | 15.5 |  |  | — |  |  | 275.3 |
General and administrative expenses | 71.4 |  |  | 29.0 |  |  | 3.1 |  |  | 41.3 |  |  | 144.8 |
Depreciation and amortization | 1.0 |  |  | 0.4 |  |  | 0.1 |  |  | 1.4 |  |  | 2.9 |
Operating expenses | 258.1 |  |  | 103.5 |  |  | 18.7 |  |  | 42.7 |  |  | 423.0 |
Operating income (loss) | $ | 52.0 |  |  | $ | 33.5 |  |  | $ | 1.5 |  |  | $ | (42.7) |  |  | $ | 44.3 |

7. SHARE REPURCHASE
2019 Stock Repurchase Program
On February 25, 2019, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $100 million of our outstanding common stock through March 1, 2020.
19

AMEDISYS, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Under the terms of the program, we were allowed to repurchase shares from time to time in open market transactions, block purchases or in private transactions in accordance with applicable federal securities laws and other legal requirements. We were allowed to enter into Rule 10b5-1 plans to effect some or all of the repurchases. The timing and the amount of the repurchases would be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors.
We did not repurchase any shares pursuant to this stock repurchase program during the three-month periods ended March 31, 2020 or March 31, 2019. The stock repurchase program expired on March 1, 2020.
8. RELATED PARTY TRANSACTIONS
During 2018, we made a $7.0 million investment in Medalogix, a healthcare predictive data and analytics company; this investment is accounted for under the equity method. During the three-month period ended March 31, 2020, we incurred costs of approximately $0.6 million in connection with the usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm's length.
9. SUBSEQUENT EVENTS
Novel Coronavirus Pandemic ("COVID-19")
In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.
On March 27, 2020, the bipartisan Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was signed into legislation. The CARES Act provides for $100 billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $30 billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers must sign an attestation confirming receipt of the funds and agree to the terms and conditions of payment. We received approximately $100 million from the first $30 billion of funds distributed to healthcare providers in April 2020. Consistent with the terms and conditions for receipt of the payment, we will utilize the funds to cover lost revenue and health care costs related to COVID-19, and we will properly and fully document the use of these funds in required quarterly reports to the U.S. Department of Health and Human Services ("HHS").
In order to properly attest to receipt of our payment, we are seeking clarity from HHS regarding the formula utilized to determine our receipt of funds and the total amount of funds available to us to be used towards lost revenue and health care expenses related to COVID-19. At this time, we have fully separated these funds into their own account and will not be utilizing any of them until additional clarity is received from HHS.
On April 24, 2020, HHS distributed an additional $20 billion in funds to healthcare providers. We did not receive, nor apply, for any additional funds from this second distribution.
Acquisitions
On April 23, 2020, we signed a definitive agreement to acquire Homecare Preferred Choice, Inc., doing business as AseraCare Hospice ("AseraCare Hospice"), a national hospice care provider with 44 locations, for a purchase price of $235 million in cash, inclusive of $32 million in payments related to the present value of the tax benefits created through the transaction (subject to customary adjustments at closing for working capital, cash indebtedness and transaction expenses). We will not use any of the funds we received from the CARES Act to fund the acquisition.
20

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations and financial condition for the three-month period ended March 31, 2020. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included herein, and the consolidated financial statements and notes and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission (“SEC”) on February 19, 2020 (the “Form 10-K”), which are incorporated herein by this reference. Historical results that appear in the condensed consolidated financial statements should not be interpreted as being indicative of future operations.
Unless otherwise provided, “Amedisys,” “we,” “our,” and the “Company” refer to Amedisys, Inc. and our consolidated subsidiaries.
Overview
We are a provider of high-quality in-home healthcare and related services to the chronic, co-morbid, aging American population, with approximately 74% of our revenue derived from Medicare for the three-month periods ended March 31, 2020 and 2019.
Our operations involve servicing patients through our three reportable business segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Our hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Our personal care segment provides patients with assistance with the essential activities of daily living. As of March 31, 2020, we owned and operated 322 Medicare-certified home health care centers, 146 Medicare-certified hospice care centers and 12 personal-care care centers in 38 states within the United States and the District of Columbia.
Care Centers Summary (Includes Unconsolidated Joint Ventures)

| Home Health |  | Hospice |  | Personal Care
As of December 31, 2019 | 321 |  |  | 138 |  |  | 12 |
Acquisitions/Startups | 1 |  |  | 9 |  |  | — |
Closed/Consolidated | — |  |  | (1) |  |  | — |
As of March 31, 2020 | 322 |  |  | 146 |  |  | 12 |

Recent Developments
Governmental Inquiries and Investigations and Other Litigation
See Note 5 – Commitments and Contingencies to our condensed consolidated financial statements for additional information regarding our corporate integrity agreements and for a discussion of and updates regarding other legal proceedings and investigations we are involved in. No assurances can be given as to the timing or outcome of these items.
Payment
In April 2020, the Centers for Medicare and Medicaid Services ("CMS") issued a proposed rule to update hospice payment rates and the wage index for fiscal year 2021. CMS estimates hospices serving Medicare beneficiaries would see an estimated 2.6% increase in payments. This increase is the result of a 3.0% market basket adjustment less a 0.4% productivity adjustment as required under the Patient Protection and Affordable Health Care Act and the Health Care and Education Reconciliation Act (collectively, "PPACA"). The rule also proposes changes to the hospice wage index by adopting the most recent Office of Management and Budget statistical area delineations with a five percent cap on wage index decreases. Finally, CMS proposed an increase in the aggregate cap amount by 2.6% to $30,743.86. Based on our analysis of the proposed rule, we expect our impact to be in line with the 2.6% increase.
The CMS Calendar Year 2020 Home Health Final Rule confirmed the implementation of the Patient-Driven Groupings Model ("PDGM") effective January 1, 2020 as well as the change in the unit of payment from a 60-day payment period to a 30-day payment period. Additionally, in an effort to eliminate fraud risks, CMS reduced requests for anticipated payment ("RAPs") for 2020 to 20% with the full elimination of RAPs in 2021. CMS estimated that the final rule would result in a 1.3% increase in payments to home health providers. The increase is the result of a statutorily mandated 1.5% market basket increase pursuant to the Bipartisan Budget Act of 2018, reduced by 0.2% for the rural add-on. In calculating the impact, CMS also assumed that the
21

industry will make certain behavioral changes related to coding practices, low utilization payment adjustment ("LUPA") management and co-morbidities. As a result, CMS reduced reimbursement by 4.36%. We have estimated the impact of the final rule on us to be a reduction in revenue of 2.8%. Our current view is that we can offset the impact via a mix of appropriate behavioral changes and cost levers which include clinician mix and utilization. The timing of our ability to fully achieve these offsets may be impacted by the novel coronavirus pandemic.
Novel Coronavirus Pandemic ("COVID-19")
Our first quarter operations and financial performance were impacted by COVID-19. We began to experience the impacts on our operations during the second week of March, as we had declines in referral volumes and an increase in missed visits. Each of our business lines was impacted; however, the disruption was greatest in our home health segment, which experienced a referral low-point the week of April 5th. Since that time, we have seen a steady recovery in referral volumes and a corresponding drop in missed visits. In our hospice segment, our referrals hit their low-point the week of March 22nd. While hospice admission volumes have improved significantly, the slowdown in March will impact our average daily census during the second quarter of 2020. The financial impact of COVID-19 during the three-month period ended March 31, 2020 is discussed in further detail under "Results of Operations" below.
Due to the uncertainty created by COVID-19, we are unable to predict the pace of recovery, and therefore, are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows. The following factors could potentially impact the timing of recovery: the continued increase or decrease in the number of COVID-19 cases nationwide, the pace at which elective procedures begin and the utilization of these procedures, the return of patient confidence to enter a hospital or a doctor's office, the ability to access to our patients in their homes and in facilities, cost normalization around personal protective equipment ("PPE") and any future or prolonged shelter-in-place orders. Potential impacts of COVID-19 on our results include lower revenue, higher salary and wage expense related to quarantine pay and increased supply costs related to PPE. The impacts to revenue may consist of the following:
•lower volumes due to interruption of the operations of our referral sources and patients' unwillingness to accept services and
•lower reimbursement due to missed visits resulting in an increase in LUPAs and lost billing periods.
On March 27, 2020, the bipartisan Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was signed into legislation. The CARES Act provides for the following:
•$100 billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic, with the intent to help defray the significant healthcare-related expenses and lost revenue attributable to the pandemic. Of this total allocated amount, $30 billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. We received approximately $100 million from the CARES Act in April 2020; our ability to utilize and retain this amount will depend on the magnitude, timing and nature of the impact of the pandemic, as well as on the rules and requirements of the program.
•The temporary suspension of the automatic 2% reduction of Medicare claim reimbursements for the period of May 1 through December 31, 2020. We estimate the impact will increase our 2020 net service revenue by approximately $21 million.
•The deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date. Fifty percent of the deferred payroll taxes are due on December 31, 2021 with the remaining amounts due on December 31, 2022. We estimate the impact will increase our 2020 cash flow from operations by approximately $50 million.
•The temporary suspension of Medicare patient coverage criteria and documentation and care requirements and the expansion of telehealth in providing home health and hospice care to patients.
•The ability for non-physician practitioners to certify for home health, order home health services, establish and review plans of care and certify and recertify eligibility.
The well-being of our employees has been one of our top priorities during this pandemic. We have taken the following steps to support our employees: implemented up to 14 days of paid leave during any required quarantine periods; instituted work-from-home arrangements for our corporate and administrative support employees; allowed employees to temporarily suspend any 401(k) plan loan deductions; allowed employees to make a withdrawal from the 401(k) plan for coronavirus-related distributions without incurring the additional 10% early withdrawal penalty; granted access to Teladoc services to all employees and launched a COVID-19 Resource Center, which is updated daily with employee, clinical and operational resources.
The safety of our clinicians and patients has also been a focus, and as a result, we have made the following business changes: implemented a new clinical protocol requiring all clinicians to wear a surgical ear loop mask, at a minimum, on all visits
22

performed; developed a COVID-19 positive patient treatment protocol and PPE policy for clinicians treating COVID-19 symptomatic and positive patients, which includes utilizing N-95 masks, gloves, gowns and face shields and also requires surgical masks to be worn by the patient; created a centralized distribution center for all critical PPE, allowing us to flex our inventory on a care center by care center basis, based on need and demand; sourced enough PPE to have four months of surgical masks, six months of N-95 masks, and one month of gowns with another two months of gowns on order. For all other critical PPE, we have an average of three months of inventory on hand and will be continuing to source more. We have had success in utilizing both traditional and non-traditional suppliers for our PPE needs. While we were very fortunate to secure the supplies needed, we faced significantly higher per unit cost for the purchase of PPE.
Acquisitions
On January 1, 2020, we acquired Asana Hospice ("Asana"), a hospice provider with locations in Pennsylvania, Ohio, Texas, Missouri and Kansas for a purchase price of $66.3 million, net of cash acquired.
On March 1, 2020, we acquired the regulatory assets of a home health provider in Washington for a purchase price of $3.0 million.
As we continue to focus on inorganic expansion in all three segments, we anticipate incurring acquisition and integration costs throughout 2020. During the three-month period ended March 31, 2020, we incurred approximately $2 million in costs related to various acquisitions and the integration of Compassionate Care Hospice ("CCH") and Asana.
Results of Operations
Three-Month Period Ended March 31, 2020 Compared to the Three-Month Period Ended March 31, 2019
Consolidated
The following table summarizes our consolidated results of operations (amounts in millions):

| For the Three-Month Periods Ended March 31, |  |
| 2020 |  | 2019
Net service revenue | $ | 491.7 |  |  | $ | 467.3 |
Gross margin, excluding depreciation and amortization | 206.0 |  |  | 192.0 |
% of revenue | 41.9 | % |  | 41.1 | %
Other operating expenses | 156.8 |  |  | 144.8 |
% of revenue | 31.9 | % |  | 31.0 | %
Depreciation and amortization | 5.3 |  |  | 2.9 |
Operating income | 43.9 |  |  | 44.3 |
Total other expense | (2.5) |  |  | (1.8) |
Income tax expense | (9.4) |  |  | (10.9) |
Effective income tax rate | 22.6 | % |  | 25.6 | %
Net income | 32.0 |  |  | 31.6 |
Net income attributable to noncontrolling interests | (0.2) |  |  | (0.3) |
Net income attributable to Amedisys, Inc. | $ | 31.8 |  |  | $ | 31.3 |

Overall, our operating income was relatively flat on a revenue increase of $24 million. Our results for the three-month period ended March 31, 2020 include the acquisitions of CCH on February 1, 2019, RoseRock Healthcare ("RoseRock") on April 1, 2019 and Asana on January 1, 2020. For the quarter, these acquisitions contributed approximately $53 million in revenue and an operating loss of approximately $2 million, which is inclusive of $2 million in acquisition and integration costs and $2 million in intangibles amortization. For the first quarter of 2019, our acquisitions contributed approximately $32 million in revenue and an operating loss of $2 million, which is inclusive of $6 million in acquisition and integration costs.
Our performance for the three-month period ended March 31, 2020 was impacted by disruption associated with COVID-19 and the transition to PDGM. Our home health segment experienced the largest revenue impact related to COVID-19, which reduced both volumes and reimbursement. Our home health segment was also impacted by the 2020 changes in reimbursement under PDGM; however, we were able to overcome a portion of the PDGM rate cut via changes in discipline mix and clinician
23

utilization, which are described in more detail below. Our operating results also reflect a 0.9% increase in our other operating expenses as a percentage of revenue compared to prior year; this increase is inclusive of approximately $2 million and $6 million in acquisition and integration costs in 2020 and 2019, respectively. Excluding the acquisition and integration costs in 2020 and 2019, our other operating expenses as a percentage of revenue increased 1.8% compared to prior year due to the addition of resources to support growth (primarily business development employees), investments related to PDGM and planned wage increases.
Home Health Segment
The following table summarizes our home health segment results of operations:

| For the Three-Month Periods Ended March 31, |  |
| 2020 |  | 2019
Financial Information (in millions): |  |  |
Medicare | $ | 203.9 |  |  | $ | 213.4 |
Non-Medicare | 99.7 |  |  | 96.7 |
Net service revenue | 303.6 |  |  | 310.1 |
Cost of service | 179.8 |  |  | 185.7 |
Gross margin | 123.8 |  |  | 124.4 |
Other operating expenses | 76.7 |  |  | 72.4 |
Operating income | $ | 47.1 |  |  | $ | 52.0 |
Same Store Growth (1): |  |  |
Medicare revenue | (4 | %) |  | 4 | %
Non-Medicare revenue | 3 | % |  | 22 | %
Total admissions | 3 | % |  | 6 | %
Total volume (2) | 1 | % |  | 6 | %
Key Statistical Data - Total (3): |  |  |
Admissions | 85,975 |  |  | 83,969 |
Recertifications | 40,541 |  |  | 41,795 |
Total volume | 126,516 |  |  | 125,764 |
Medicare completed episodes (6) | 75,636 |  |  | 75,483 |
Average Medicare revenue per completed episode (4) (6) | $ | 2,734 |  |  | $ | 2,838 |
Medicare visits per completed episode (5) (6) | 15.8 |  |  | 17.2 |
Visiting Clinician Cost per Visit | $ | 84.01 |  |  | $ | 81.05 |
Clinical Manager Cost per Visit | $ | 8.97 |  |  | $ | 8.01 |
Total Cost per Visit | $ | 92.98 |  |  | $ | 89.06 |
Visits | 1,933,445 |  |  | 2,085,088 |

(1) Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
(2) Total volume includes all admissions and recertifications.
(3) Total includes acquisitions and denovos.
(4) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode for the three-month period ended March 31, 2020 reflects the transition to PDGM during the quarter and therefore includes reimbursement under both the 60-day episode of care (pre-PDGM) payment rate and the 30-day period of care (PDGM) payment rate.
(5) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.
(6) Prior year amounts have been recast to conform to the current year calculation.
24

Operating Results
Overall, our operating income decreased $5 million on a $7 million decrease in net service revenue and a $1 million decrease in gross margin. Our revenue and gross margin were impacted by both COVID-19 and the transition to PDGM. The COVID-19 pandemic impacted both volumes and reimbursement resulting in a decrease in net service revenue of $6 million and gross margin of $4 million; the gross margin impact is inclusive of additional costs related to clinician training, quarantine pay and the purchase of personal protective equipment. As expected, our revenue and gross margin were also impacted by the 2020 changes in reimbursement under PDGM, which resulted in a decrease in net service revenue and gross margin of approximately $6 million. We were able to overcome the majority of this rate cut via changes related to clinician utilization and discipline mix, which are described in more detail below. Lastly, our operating expenses increased as a result of the addition of resources to support volume growth, planned wage increases and investments related to PDGM.
Net Service Revenue
Our revenue decreased $7 million primarily due to the impact of the 2020 change in reimbursement under PDGM and COVID-19, partially offset by a 1% increase in total volume and a reduction in price concessions. We have estimated the impact of COVID-19 to be a reduction to revenue of approximately $6 million based on the decline in volume near the end of the quarter as well as an increase in LUPAs and lost billing periods resulting from missed visits related to COVID-19. We have estimated the impact of the 2020 change in reimbursement to be a reduction to revenue of $6 million. The 2020 change in reimbursement and the disruption related to COVID-19 are evident in our Medicare revenue per completed episode, which decreased 4%.
Cost of Service, Excluding Depreciation and Amortization
Our cost of service consists of costs associated with direct clinician care in the homes of our patients as well as the cost of clinical managers who monitor the overall delivery of care. Overall, our total cost of service decreased 3% on a 7% decrease in total visits driven by COVID-19 disruption, improvements in clinician utilization as evidenced by a decline of 1.4 visits per completed episode year over year, and optimization of discipline mix. These items were partially offset by a 4% increase in our total cost per visit, which was driven by planned wage increases, changes in our staffing model and approximately $1 million in costs associated with COVID-19 related to clinician training, quarantine pay and the purchase of personal protective equipment. In addition, a portion of our costs are fixed, so our cost per visit metric will increase as visits decline.
Other Operating Expenses
Other operating expenses increased approximately $4 million primarily due to an increase in salaries and benefits expense as a result of the addition of resources to support volume growth, planned wage increases and investments related to PDGM. Additionally, changes in our home health care center staffing resulted in a shift of some office staff from cost of service to other operating expenses totaling approximately $1 million.
25

Hospice Segment
The following table summarizes our hospice segment results of operations:

| For the Three-Month Periods Ended March 31, |  |
| 2020 |  | 2019
Financial Information (in millions): |  |  |
Medicare | $ | 160.5 |  |  | $ | 130.7 |
Non-Medicare | 8.9 |  |  | 6.3 |
Net service revenue | 169.4 |  |  | 137.0 |
Cost of service | 91.8 |  |  | 74.1 |
Gross margin | 77.6 |  |  | 62.9 |
Other operating expenses | 39.3 |  |  | 29.4 |
Operating income | $ | 38.3 |  |  | $ | 33.5 |
Same Store Growth (1): |  |  |
Medicare revenue | 5 | % |  | 9 | %
Hospice admissions | 1 | % |  | 5 | %
Average daily census | 4 | % |  | 8 | %
Key Statistical Data - Total (2): |  |  |
Hospice admissions | 11,318 |  |  | 9,711 |
Average daily census | 12,046 |  |  | 9,982 |
Revenue per day, net | $ | 154.55 |  |  | $ | 152.56 |
Cost of service per day | $ | 83.78 |  |  | $ | 82.43 |
Average discharge length of stay | 98 |  |  | 98 |

(1) Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.
(2) Total includes acquisitions and denovos.
Operating Results
On February 1, 2019, we acquired CCH, which owned and operated 53 hospice care centers. On April 1, 2019, we acquired RoseRock, which owned and operated one hospice care center. On January 1, 2020, we acquired Asana, which owned and operated eight hospice care centers. Acquisitions are included in our consolidated financial statements from their respective acquisition dates. As a result, our hospice segment operating results for 2020 and 2019 are not fully comparable.
Overall, our operating income increased $5 million on a $32 million increase in net service revenue. Our operating results for the quarter were positively impacted by continued growth and by our acquisitions. Our acquisitions contributed approximately $53 million in revenue and $5 million in operating income to our hospice segment's results for the three-month period ended March 31, 2020 and approximately $32 million in revenue and $5 million in operating income for the three-month period ended March 31, 2019. Our operating results were impacted by both COVID-19, as described in more detail below, and the 2020 change in reimbursement, which resulted in an increase in revenue of $1 million but a reduction in gross margin of less than $1 million for the quarter, as the majority of the revenue increase was passed through to our general inpatient and respite facilities.
Net Service Revenue
Our hospice revenue increased $32 million, approximately $21 million of which is attributable to our acquisition activity. The remaining $11 million increase is the result of a 4% increase in our average daily census, a 0.5% increase in reimbursement effective for services provided from October 1, 2019 and a reduction in our revenue price concessions. The impact of COVID-19 on our hospice segment was less than $1 million. We experienced a slight decline in admissions near the end of the quarter, but average daily census remained strong. A continued decline in admissions could have a negative impact on our future average daily census.
26

Cost of Service, Excluding Depreciation and Amortization
Our hospice cost of service increased $18 million, approximately $14 million of which is attributable to our acquisition activity. The remaining $4 million increase is primarily due to a 4% increase in average daily census, planned wage increases and an increase in our general inpatient and respite facility costs as the majority of the reimbursement increase, which became effective October 1, 2019, will be passed through to these facilities.
Other Operating Expenses
Other operating expenses increased $10 million, approximately $8 million of which is related to our acquisition activity. The remaining $2 million increase is due to increases in other care center related expenses, primarily salaries and benefits due to the addition of resources to support census growth and planned wage increases.
Personal Care Segment
The following table summarizes our personal care segment results of operations:

| For the Three-Month Periods Ended March 31, |  |
| 2020 |  | 2019
Financial Information (in millions): |  |  |
Medicare | $ | — |  |  | $ | — |
Non-Medicare | 18.7 |  |  | 20.2 |
Net service revenue | 18.7 |  |  | 20.2 |
Cost of service | 14.1 |  |  | 15.5 |
Gross margin | 4.6 |  |  | 4.7 |
Other operating expenses | 3.4 |  |  | 3.2 |
Operating income | $ | 1.2 |  |  | $ | 1.5 |
Key Statistical Data - Total (1): |  |  |
Billable hours | 752,077 |  |  | 833,617 |
Clients served | 11,770 |  |  | 12,801 |
Shifts | 333,464 |  |  | 376,182 |
Revenue per hour | $ | 24.87 |  |  | $ | 24.19 |
Revenue per shift | $ | 56.09 |  |  | $ | 53.60 |
Hours per shift | 2.3 |  |  | 2.2 |

(1) Total includes acquisitions.
Operating Results
Operating income related to our personal care segment remained relatively flat as net service revenue and cost of service both decreased $1 million; other operating expenses also remained relatively flat. Throughout 2019, we made efforts to reduce lower margin shifts; while these efforts have resulted in lower volumes, they have led to a 130 basis point improvement in gross margin as a percentage of revenue. The net impact of COVID-19 on our personal care segment was minimal as the reduction in revenue was largely offset by a reduction in costs as most of our personal care employees are paid on an hourly basis.
27

Corporate
The following table summarizes our corporate results of operations:

| For the Three-Month Periods Ended March 31, |  |
| 2020 |  | 2019
Financial Information (in millions): |  |  |
Other operating expenses | $ | 39.0 |  |  | $ | 41.3 |
Depreciation and amortization | 3.7 |  |  | 1.4 |
Total operating expenses | $ | 42.7 |  |  | $ | 42.7 |

Corporate expenses consist of costs related to our executive management and corporate and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.
Corporate total operating expenses remained flat during the three-month period ended March 31, 2020 compared to 2019. Excluding the impact of our 2020 and 2019 acquisitions which includes corporate and administrative support functions, intangibles amortization and acquisition and integration costs, total operating expenses increased approximately $1 million which represents 3% of our $24 million increase in revenue. The increase is due to increased functional support, planned wage increases, fees related to our ClearCare partnership and lower gains on the sale of fleet vehicles in 2020 as compared to 2019; these items were partially offset by decreases in travel and training expense and IT-related expenses.
Liquidity and Capital Resources
Cash Flows
The following table summarizes our cash flows for the periods indicated (amounts in millions):

| For the Three-Month Periods Ended March 31, |  |
| 2020 |  | 2019
Cash provided by operating activities | $ | 6.0 |  |  | $ | 20.1 |
Cash used in investing activities | (70.7) |  |  | (328.9) |
Cash provided by financing activities | 146.0 |  |  | 299.2 |
Net increase (decrease) in cash, cash equivalents and restricted cash | 81.3 |  |  | (9.6) |
Cash, cash equivalents and restricted cash at beginning of period | 96.5 |  |  | 20.2 |
Cash, cash equivalents and restricted cash at end of period | $ | 177.8 |  |  | $ | 10.6 |

Cash provided by operating activities decreased $14.1 million during the three-month period ended March 31, 2020 compared to the three-month period ended March 31, 2019 primarily due to a decrease in our cash collections as result of our transition to PDGM.
Cash used in investing activities decreased $258.2 million during the three-month period ended March 31, 2020 compared to the three-month period ended March 31, 2019 as a result of our acquisition of CCH in 2019.
Cash provided by financing activities decreased $153.2 million during the three-month period ended March 31, 2020 compared to the three-month period ended March 31, 2019 primarily due to borrowings under our Amended Credit Agreement to fund the CCH acquisition in 2019.
28

Liquidity
Typically, our principal source of liquidity is the collection of our patient accounts receivable, primarily through the Medicare program. In addition to our collection of patient accounts receivable, from time to time, we can and do obtain additional sources of liquidity by the incurrence of additional indebtedness. In order to mitigate the risk of any cash availability issues related to COVID-19, we borrowed $150 million under our Amended Credit Agreement in March 2020. While we have experienced disruption in our business volume, we have not seen a change in our collection trends and remain confident in our ability to fund our operations.
During the three-month period ended March 31, 2020, we spent $1.4 million in capital expenditures as compared to $1.2 million during the three-month period ended March 31, 2019. Our capital expenditures for 2020 are expected to be approximately $6.0 million to $8.0 million, excluding the impact of any future acquisitions.
As of March 31, 2020, we had $174.8 million in cash and cash equivalents and $299.8 million in availability under our $550.0 million Revolving Credit Facility.
Based on our operating forecasts and our debt service requirements, we believe we will have sufficient liquidity to fund our operations, capital requirements and debt service requirements.
Outstanding Patient Accounts Receivable
Our patient accounts receivable increased $31.0 million from December 31, 2019 to March 31, 2020; $8.9 million of the increase is related to acquisition activity. We also experienced an increase related to the reduction in RAPs under PDGM. Our cash collection as a percentage of revenue was 102% and 101% for the three-month periods ended March 31, 2020 and 2019, respectively. Our days revenue outstanding at March 31, 2020 was 46.6 days which is an increase of 5.7 days from December 31, 2019 and an increase of 5.4 days from March 31, 2019. As anticipated, the transition to PDGM has negatively impacted our days revenue outstanding; the estimated impact is 5.9 days.
Our patient accounts receivable includes unbilled receivables and are aged based upon our initial service date. We monitor unbilled receivables on a care center by care center basis to ensure that all efforts are made to bill claims within timely filing deadlines. Our unbilled patient accounts receivable can be impacted by acquisition activity, probe edits or regulatory changes which result in additional information or procedures needed prior to billing. The timely filing deadline for Medicare is one year from the date the episode was completed and varies by state for Medicaid-reimbursable services and among insurance companies and other private payors.
The following schedules detail our patient accounts receivable, by payor class, aged based upon initial date of service (amounts in millions, except days revenue outstanding):
29

| 0-90 |  | 91-180 |  | 181-365 |  | Over 365 |  | Total
At March 31, 2020: |  |  |  |  |  |  |  |  |
Medicare patient accounts receivable | $ | 143.3 |  |  | $ | 12.6 |  |  | $ | 5.9 |  |  | $ | 1.2 |  |  | $ | 163.0 |
Other patient accounts receivable: |  |  |  |  |  |  |  |  |
Medicaid | 18.9 |  |  | 6.1 |  |  | 4.0 |  |  | — |  |  | 29.0 |
Private | 69.6 |  |  | 5.2 |  |  | 1.8 |  |  | — |  |  | 76.6 |
Total | $ | 88.5 |  |  | $ | 11.3 |  |  | $ | 5.8 |  |  | $ | — |  |  | $ | 105.6 |
Total patient accounts receivable |  |  |  |  |  |  |  |  | $ | 268.6 |
Days revenue outstanding (1) |  |  |  |  |  |  |  |  | 46.6 |
| 0-90 |  | 91-180 |  | 181-365 |  | Over 365 |  | Total
At December 31, 2019: |  |  |  |  |  |  |  |  |
Medicare patient accounts receivable | $ | 115.2 |  |  | $ | 13.8 |  |  | $ | 6.8 |  |  | $ | 1.0 |  |  | $ | 136.8 |
Other patient accounts receivable: |  |  |  |  |  |  |  |  |
Medicaid | 22.6 |  |  | 5.7 |  |  | 4.0 |  |  | — |  |  | 32.3 |
Private | 60.0 |  |  | 6.3 |  |  | 2.2 |  |  | — |  |  | 68.5 |
Total | $ | 82.6 |  |  | $ | 12.0 |  |  | $ | 6.2 |  |  | $ | — |  |  | $ | 100.8 |
Total patient accounts receivable |  |  |  |  |  |  |  |  | $ | 237.6 |
Days revenue outstanding (1) |  |  |  |  |  |  |  |  | 40.9 |

(1)Our calculation of days revenue outstanding is derived by dividing our ending patient accounts receivable at March 31, 2020 and December 31, 2019 by our average daily patient revenue for the three-month periods ended March 31, 2020 and December 31, 2019, respectively.
Indebtedness
First Amendment to Amended and Restated Credit Agreement
On February 4, 2019, we entered into the First Amendment to our Credit Agreement (as amended by the First Amendment, the "Amended Credit Agreement"). The Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $725.0 million, which includes a $550.0 million Revolving Credit Facility under the Credit Agreement and a term loan facility with a principal amount of up to $175.0 million (the "Term Loan Facility" and collectively with the Revolving Credit Facility, the "Credit Facility"), which was added by the First Amendment.
We borrowed the entire principal amount of the Term Loan Facility on February 4, 2019 in order to fund a portion of the purchase price of the CCH acquisition, with the remainder of the purchase price and associated transactional fees and expenses funded by proceeds from the Revolving Credit Facility.
Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 3.2% and 4.2% for the three-month periods ended March 31, 2020 and March 31, 2019, respectively. Our weighted average interest rate for borrowings under our $175.0 million Term Loan Facility was 3.2% for the three-month period ended March 31, 2020 and 4.2% for the period February 4, 2019 to March 31, 2019.
As of March 31, 2020, our consolidated leverage ratio was 1.5, our consolidated interest coverage ratio was 16.6 and we are in compliance with our covenants under the Amended Credit Agreement.
As of March 31, 2020, our availability under our $550.0 million Revolving Credit Facility was $299.8 million as we have $220.0 million outstanding in borrowings and $30.2 million outstanding in letters of credit.
See Note 4 - Long Term Obligations to our condensed consolidated financial statements for additional details on our outstanding long-term obligations.
30

Share Repurchase
2019 Stock Repurchase Program
On February 25, 2019, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $100 million of our outstanding common stock through March 1, 2020.
Under the terms of the program, we were allowed to repurchase shares from time to time in open market transactions, block purchases or in private transactions in accordance with applicable federal securities laws and other legal requirements. We were allowed to enter into Rule 10b5-1 plans to effect some or all of the repurchases. The timing and the amount of the repurchases would be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors.
We did not repurchase any shares pursuant to this stock repurchase program during the three-month periods ended March 31, 2020 or March 31, 2019. The stock repurchase program expired on March 1, 2020.
Inflation
We do not believe inflation has significantly impacted our results of operations.
Critical Accounting Estimates
See Part II, Item 7 – Critical Accounting Estimates and our consolidated financial statements and related notes in Part II, Item 8 of our 2019 Annual Report on Form 10-K, for accounting policies and related estimates we believe are the most critical to understanding our condensed consolidated financial statements, financial condition and results of operations and which require complex management judgment and assumptions, or involve uncertainties. These critical accounting estimates include revenue recognition and goodwill and other intangible assets. There have not been any changes to our significant accounting policies or their application since we filed our 2019 Annual Report on Form 10-K.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to market risk from fluctuations in interest rates. Our Revolving Credit Facility carries a floating interest rate which is tied to the Eurodollar rate (i.e. LIBOR) and the Prime Rate and therefore, our condensed consolidated statements of operations and our condensed consolidated statements of cash flows are exposed to changes in interest rates. As of March 31, 2020, the total amount of outstanding debt subject to interest rate fluctuations was $390.6 million. A 1.0% interest rate change would cause interest expense to change by approximately $3.9 million annually, assuming the Company makes no principal repayments.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
We have established disclosure controls and procedures which are designed to provide reasonable assurance of achieving their objectives and to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized, disclosed and reported within the time periods specified in the SEC’s rules and forms. This information is also accumulated and communicated to our management and Board of Directors to allow timely decisions regarding required disclosure.
In connection with the preparation of this Quarterly Report on Form 10-Q, as of March 31, 2020, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act.
Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of March 31, 2020, the end of the period covered by this Quarterly Report.
31

Changes in Internal Controls
There have been no changes in our internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) that have occurred during the quarter ended March 31, 2020, that have materially impacted, or are reasonably likely to materially impact, our internal control over financial reporting.
Inherent Limitations on Effectiveness of Controls
Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls’ effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and, based on an evaluation of our controls and procedures, our principal executive officer and our principal financial officer concluded our disclosure controls and procedures were effective at a reasonable assurance level as of March 31, 2020, the end of the period covered by this Quarterly Report.
32

PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
See Note 5 - Commitments and Contingencies to the condensed consolidated financial statements for information concerning our legal proceedings.
ITEM 1A. RISK FACTORS
There have been no material changes in the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2019, except for the risk factor below.
Our business may be materially adversely affected by the ongoing novel coronavirus ("COVID-19") pandemic.
The recent outbreak of the COVID-19 pandemic has resulted in a general economic downturn and volatility in the stock market and has also caused and may continue to cause a decrease in our patient volumes and revenues, an increase in costs and an inability to access our patients and referral sources and could lead to staffing and medical supply shortages, any of which, or a combination of which, could have a material adverse effect on our business and financial results. The ultimate impact of COVID-19, including the impact on our liquidity, financial condition and results of operations, is uncertain and will depend on many factors and future developments, which are highly uncertain and cannot be predicted at this time, including the severity, scope and length of time that the pandemic continues, its impact on the national and global economy, its effect on the demand for our services, our ability to ensure the safety of our patients and employees and the actions taken by federal, state and local authorities to contain or treat the COVID-19 pandemic.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
The following table provides the information with respect to purchases made by us of shares of our common stock during each of the months during the three-month period ended March 31, 2020:

Period | (a) Total Number of Shares (or Units) Purchased |  |  | (b) Average Price Paid per Share (or Unit) |  | (c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs |  | (d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) That May Yet Be Purchased Under the Plans or Programs (2)
January 1, 2020 to January 31, 2020 | 10,542 |  |  |  | $ | 173.73 |  |  | — |  |  | $ | 100,000,000 |
February 1, 2020 to February 29, 2020 | 6,651 |  |  |  | 196.79 |  |  | — |  |  | 100,000,000 |
March 1, 2020 to March 31, 2020 | 5,046 |  |  |  | 180.24 |  |  | — |  |  | — |
| 22,239 |  | (1) |  |  | $ | 182.10 |  |  | — |  |  | $ | — |

(1)Includes shares of common stock surrendered to us by certain employees to satisfy tax withholding obligations in connection with the vesting of non-vested stock previously awarded to such employees under our 2008 and 2018 Omnibus Incentive Compensation Plans.
(2)On February 25, 2019, our Board of Directors authorized a share repurchase program, pursuant to which we could repurchase up to $100 million of our outstanding shares of common stock through March 1, 2020, when the share repurchase program expired.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
None.
33

ITEM 6. EXHIBITS
The exhibits marked with the cross symbol (†) are filed and the exhibits marked with a double cross (††) are furnished with this Form 10-Q. Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K.

Exhibit Number | Document Description |  | Report or Registration Statement |  | SEC File or Registration Number |  | Exhibit or Other Reference
3.1 | Composite of Certificate of Incorporation of the Company inclusive of all amendments through June 14, 2007 |  | The Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 |  | 0-24260 |  | 3.1 |
3.2 | Composite of By-Laws of the Company inclusive of all amendments through October 17, 2019 |  | The Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 |  | 0-24260 |  | 3.2 |
†31.1 | Certification of Paul B. Kusserow, President and Chief Executive Officer (principal executive officer), pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |
†31.2 | Certification of Scott G. Ginn, Chief Financial Officer (principal financial officer), pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |
††32.1 | Certification of Paul B. Kusserow, President and Chief Executive Officer (principal executive officer), pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |
††32.2 | Certification of Scott G. Ginn, Chief Financial Officer (principal financial officer), pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |
†101.INS | Inline XBRL Instance - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |  |  |  |  |  |
†101.SCH | Inline XBRL Taxonomy Extension Schema Document |  |  |  |  |  |
†101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  |  |  |
†101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase |  |  |  |  |  |
†101.LAB | Inline XBRL Taxonomy Extension Labels Linkbase Document |  |  |  |  |  |
†101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  |  |  |
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |  |  |  |  |  |

34

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

A MEDISYS, I NC. (Registrant) |  |
By: |  | /s/ SCOTT G. GINN
|  | Scott G. Ginn,
|  | Principal Financial Officer and
|  | Duly Authorized Officer

Date: May 7, 2020
35